Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.

Granzyme B is important in autoimmune skin diseases and could be a new treatment target.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Blocking IL-17 signaling may reduce skin inflammation and delay aging.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.

Laser treatment and deroofing are effective options for hidradenitis suppurativa.

Recognizing nail changes helps diagnose and treat non-infectious skin diseases.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Improving access to hidradenitis suppurativa care can reduce social disparities.

Scalp psoriasis inflammation is mainly caused by bacteria-related triggers.

New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.

New treatments offer hope for better managing hidradenitis suppurativa.

Technology, like mobile apps and AI, is improving skin condition diagnosis and treatment.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Biologics for severe asthma have known side effects, but some new risks need more study.

Mogamulizumab can cause hair loss, often linked to a better treatment response.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Biosimilars lower costs but don't significantly improve access.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.